Edgar Filing: LEMAITRE VASCULAR INC - Form 8-K

LEMAITRE VASCULAR INC Form 8-K December 03, 2015

#### **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION

## **WASHINGTON, DC 20549**

#### FORM 8-K

### **CURRENT REPORT**

### **PURSUANT TO SECTION 13 OR 15(D)**

### OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 3, 2015

LeMaitre Vascular, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction **001-33092** (Commission

04-2825458 (IRS Employer

of Incorporation)

File Number)

**Identification No.)** 

### Edgar Filing: LEMAITRE VASCULAR INC - Form 8-K

# 43 Second Avenue Burlington, Massachusetts (Address of Principal Executive Offices)

01803 (Zip Code)

(781) 221-2266

(Registrant s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### Item 7.01. Regulation FD Disclosure.

On December 3, 2015, LeMaitre Vascular, Inc. (the Company) is hosting an investor and analyst meeting (Analyst Day) beginning at 8:30 a.m. ET at Ruth's Chris Steak House, located at 148 W. 5\$t., New York, New York. During this meeting, management is providing investors and analysts with an overview of the Company's business, positioning, overall corporate strategy and future growth opportunities as well as reiterating the Company's financial outlook for the fourth quarter and full year 2015 previously announced on October 27, 2015. The Analyst Day presentation materials are attached hereto as Exhibit 99.1 and incorporated herein by reference. The Company may use these materials at one or more subsequent conferences or meetings with analysts and investors. The presentation materials will also be available online at <a href="https://www.lemaitre.com/investor">www.lemaitre.com/investor</a> as of December 3, 2015.

The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed filed for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

#### Item 9.01 Financial Statements and Exhibits.

The following exhibit is furnished as part of this report:

(d) Exhibits.

# **Exhibit No.** Description

99.1 Analyst Day Presentation

2

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 3, 2015

LEMAITRE VASCULAR, INC.

By: /s/ Joseph P. Pellegrino, Jr.

Name: Joseph P. Pellegrino, Jr. Title: Chief Financial Officer

3

# EXHIBIT INDEX

**Exhibit No.** Description

99.1 Analyst Day Presentation

4